Guerbet in figures

Medical imaging: a comprehensive product range

Our portfolio contains contrast media for X-ray imaging, for MRI and for interventional radiology. As well as a range of injection solutions and related medical disposables.

Patient diagnostics: 19 million doses given in 2012

More than 60,000 health professionals rely on our contrast agents to diagnose disease and assess treatment efficacy.

10% of turnover and 210 employees devoted to R&D

Advancing in the diagnosis of major diseases (cardiovascular diseases, cancers, diseases of the central nervous system), while reconciling efficacy and cost containment, are at the heart of Guerbet's mission. 

Involvement in more than 100 R&D partnerships

With its worldwide network of scientific partners in both the public and private sectors, Guerbet is fueling progress in imaging technologies.

Lipiodol, the pioneering contrast agent.

First discovered in 1901, Lipiodol in 1926 became the first iodized contrast agent to be used in radiology. It still serves today in diagnostic and interventional imaging.

1,400 employees and 20 affiliates worldwide.

Our products and services are made available in more than 70 countries through our affiliates and network of agents.

Turnover of €403m in 2012

Growth in 2012 annual revenue was driven by a particularly strong performance in the second half (+ 10.9%) compared with the first six months. These gains were achieved in Europe, and mainly in France, Germany and Switzerland.

Four specialized production plants

Guerbet has acquired the facilities necessary for high-performance industrial production: 2 chemical sites for the manufacture of active substances, 2 pharmaceutical sites for the dissolution and packaging of contrast agents.

Dotarem leader in Europe

Used for 23 years in clinical practice, Dotarem has been injected to more than 37 million patients in 70 countries.